Eisai Gives Full Aduhelm Responsibility To Biogen Under Amended Agreement
Japanese Pharma Trades 50-50 Deal For Single-Digit Royalty
Executive Summary
The companies amended the terms of their Alzheimer’s collaboration to give Biogen full decision-making control over Aduhelm immediately. Eisai’s 50% share of profits and losses from the drug switches to a 2% royalty in 2023. The partners’ agreement for Eisai-led lecanemab remains intact.
You may also be interested in...
How Biogen’s Aduhelm Bet Became A Commercial Bust
Biogen caught a lucky break in getting the first FDA approval for a potentially disease-modifying Alzheimer’s therapy, but doubt over clinical benefit and commercial missteps have left Biogen in a precarious position a year later.
How Biogen’s Aduhelm Bet Became A Commercial Bust
Biogen caught a lucky break in getting the first FDA approval for a potentially disease-modifying Alzheimer’s therapy, but doubt over clinical benefit and commercial missteps have left Biogen in a precarious position a year later.
Eisai’s Lecanemab BLA Filing A Key Step For Ailing Biogen
Aduhelm commercialization was a bust, so Biogen’s next big hope for a potential blockbuster Alzheimer’s therapy is partner Eisai’s amyloid protofibril-targeting antibody lecanemab.